Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px
Collaboration › Details

Bicycle Therapeutics–Canaccord Genuity: investor conference, 201908 supply service Bicycle presents at Canaccord Genuity Growth Conference in Boston

 

Period Period 2019-08-07
Region Region Boston, MA
  Country United States (USA)
Organisations Partner, 1st Bicycle Therapeutics plc (Nasdaq: BCYC)
  Group Bicycle Therapeutics (Group)
  Partner, 2nd Canaccord Genuity (Group)
Products Product Canaccord Genuity Annual Growth Conference 2019 Boston
  Product 2 Bicycles® platform (bicyclic peptides)
Person Person Green, Sara (Ten Bridge Communications 201908)
     

Bicycle Therapeutics plc. (8/1/19). "Press Release: Bicycle Therapeutics to Present at the Canaccord Genuity 39th Annual Growth Conference". Cambridge & Boston, MA.

Bicycle Therapeutics plc, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will present at the Canaccord Genuity 39th Annual Growth Conference on Wednesday, August 7, 2019 at 1:30 p.m. EDT in Boston, MA.

A live webcast of the presentation can be accessed in the Investors & Media section of Bicycle’s website at www.bicycletherapeutics.com. An archived replay of the webcast will be available for 90 days following the presentation date.


About Bicycle Therapeutics

Bicycle Therapeutics plc (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles®, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle’s lead product candidate, BT1718, is a Bicycle Toxin Conjugate being investigated in an ongoing Phase I/IIa clinical trial in collaboration with the Centre for Drug Development of Cancer Research UK. Bicycle is headquartered in Cambridge, U.K. with many key functions and members of its leadership team located in Lexington, MA. For more information, visit BicycleTherapeutics.com, connect with us on LinkedIn and follow us on Twitter at @Bicycle_tx.


Media:
Ten Bridge Communications
Sara Green
sgreen@tenbridgecommunications.com
+1-617-233-1714

Investors:
Argot Partners
Maeve Conneighton
maeve@argotpartners.com
+1-212-600-1902

   
Record changed: 2019-08-21

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for Bicycle Therapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BIO-Europe 2019 Partnering Open BEU2019 650x80px




» top